Tivozanib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 198 publications

Preclinical Ocular Pharmacokinetics and Efficacy of Novel Tivozanib Eye Drops for Neovascular Age-Related Macular Degeneration.

Preclinical Ocular Pharmacokinetics and Efficacy of Novel Tivozanib Eye Drops for Neovascular Age-Related Macular Degeneration.

Journal: Investigative ophthalmology & visual science

Published: July 27, 2026

Development and Validation of an LC-MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma.

Development and Validation of an LC-MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 10, 2026

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics.

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics.

Journal: Frontiers in pharmacology

Published: May 21, 2026

Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.

Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.

Journal: Risk management and healthcare policy

Published: April 25, 2026

Real-world Effectiveness of Single-Agent Tivozanib in Patients with Metastatic Clear Cell Renal Cell Carcinoma.

Real-world Effectiveness of Single-Agent Tivozanib in Patients with Metastatic Clear Cell Renal Cell Carcinoma.

Journal: Journal of kidney cancer and VHL

Published: March 27, 2026

Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors

Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors

Journal: Aktuelle Urologie

Published: February 05, 2026

Mechanistic insights into Gwt1-substrate interactions and antifungal drug discovery via molecular dynamics and virtual screening.

Mechanistic insights into Gwt1-substrate interactions and antifungal drug discovery via molecular dynamics and virtual screening.

Journal: Journal of biomolecular structure & dynamics

Published: January 12, 2026

A Systematic Review Comparing Sex-Specific Outcomes of Prospective Clinical Trials and Subsequent Real-World Data Focusing on Systemic Treatment Options for Renal Cell Cancer.

A Systematic Review Comparing Sex-Specific Outcomes of Prospective Clinical Trials and Subsequent Real-World Data Focusing on Systemic Treatment Options for Renal Cell Cancer.

Journal: Urologia internationalis

Published: December 03, 2025

Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.

Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

Published: November 25, 2025

Ocular pharmacokinetics of tivozanib eye drops in patients with neovascular age-related macular degeneration: comparison with phase 1 trials of oral tivozanib in solid tumors.

Ocular pharmacokinetics of tivozanib eye drops in patients with neovascular age-related macular degeneration: comparison with phase 1 trials of oral tivozanib in solid tumors.

Journal: International journal of retina and vitreous

Published: November 12, 2025

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Journal: Cancers

Published: October 16, 2025

Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis.

Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis.

Journal: BMC cancer

Published: October 10, 2025

Showing 1-12 of 198

Last Updated: 09/26/2026